General Description

Kazia Therapeutics

Youtube Subscribe

Ticker: KZIA

Sector: Biotechnology

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company. The top 2 shareholders own 63% of the company, 22% of Kazia.

Extended Summary

Kazia Therapeutics

Kazia Therapeutics (KZIA) News, Articles, Events & Latest Updates Stocktwits Join the Conversation! Build your trading network. Link your favorite assets Link Your Portfolio and become verified Sign Up Log In Log In StockTwits. Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding upcoming data present... 7 weeks ago - PRNewsWire KAZIA THERAPEUTICS: PNOC022 CLINICAL DATA at 2023 SOCIETY for NEURO-ONCOLOGY annual meeting. Kazia Therapeutics Limiteds (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week. The top 2 shareholders own 63% of the company, 22% of Kazia is held by insiders. It would appear that 9.8% are controlled by hedge funds. Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway.

Related Results

November 24, 2023 13:13 (London Time)